Bristol-myers Squibb Compnay

Michael Louis Doyle

Jonathan Harry Davis

Mary Struthers

Priyanka Apurva Madia

Disclosed herein are fusion proteins comprising: (a) a first polypeptide comprising Interleukin-2 (IL2); and (b) a second polypeptide, fused in frame to the first polypeptide, wherein the second polypeptide comprises an extracellular domain of Interleukin-2 Receptor alpha (IL2Rα), wherein IL2 or IL2Rα comprises at least one fewer glycosylation site compared to native IL2 or native IL2Rα. Methods of production and methods of therapeutic use of the fusion proteins are also disclosed.

Interleukin-2/interleukin-2 receptor alpha fusion proteins and methods of use

Disclosed herein are fusion proteins comprising: (a) a first polypeptide comprising Interleukin-2 (IL2); and (b) a second polypeptide, fused in frame to the first polypeptide, wherein the second polypeptide comprises an extracellular domain of Interleukin-2 Receptor alpha (IL2R&#x3b1;), wherein IL2 or IL2R&#x3b1; comprises at least one fewer glycosylation site compared to native IL2 or native IL2R&#x3b1;. Methods of production and methods of therapeutic use of the fusion proteins are also disclosed.

Growing community of inventors

Yardley, PA, United States of America

Michael Louis Doyle